

ersonal use only

AGM Presentation

November 2023

Important Notice & Disclaimer

1. Summary information

This presentation has been prepared by Botanix Pharmaceuticals Ltd (“Botanix”) and contains summary information about Botanix and the business conducted by it which is current as at the date of this presentation (“Presentation”) (unless otherwise indicated).

The information in this Presentation is general in nature and does not purport to be accurate nor complete, nor does it contain all of the information that an investor may require in evaluating a possible investment in Botanix, nor does it contain all the information which would be required in a disclosure document or prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). It has been prepared by Botanix with due care but no representation or warranty, express or implied, is provided in relation to the accuracy, reliability, fairness or completeness of the information, opinions or conclusions in this Presentation by Botanix or any other party.

The information in this Presentation remains subject to change without notice. Reliance should not be placed on information or opinions contained in this Presentation, and Botanix does not have any obligation to finalize, correct or update the content of this Presentation. Certain data used in this Presentation has been obtained from research, surveys or studies conducted by third parties, including industry or general publications.

To the maximum extent permitted by law, Botanix is not responsible for updating, nor undertakes to update, this Presentation. It should be read in conjunction with Botanix’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www2.asx.com.au or at <https://botanixpharma.com/category/asx-releases/>.

2. Not an offer

Neither this Presentation nor any of its contents will form the basis of any understanding, proposal, offer, invitation, contract or commitment.

3. Industry data

Certain market and industry data used in connection with or referenced in this Presentation has been obtained from public filings, research, surveys or studies made or conducted by third parties, including as published in industry-specific or general publications. Neither Botanix nor its advisers, or their respective representatives, have independently verified any such market or industry data.

4. Financial data

All dollar values are in United States dollars (\$) or US\$) unless otherwise stated. Amounts, totals and change percentages are calculated on whole numbers and not the rounded amounts presented.

5. Forward-looking statements and forecasts

This Presentation contains certain “forward-looking statements” and comments about future matters. Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercializing product candidates or research collaborations with its partners, including in Japan, the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. You are cautioned not to place undue reliance on forward-looking statements. Any such statements, opinions and estimates in this Presentation speak only as of the date hereof, are preliminary views and are based on assumptions and contingencies subject to change without notice, as are statements about market and industry trends, projections, guidance and estimates. Forward-looking statements are provided as a general guide only. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct.

Any such forward looking statements are also based on assumptions and contingencies which are subject to change, and which may ultimately prove to be materially incorrect, as are statements about market and industry trends, which are based on interpretations of current market conditions. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements (particularly in light of the current economic climate and significant volatility, uncertainty and disruption caused by the COVID-19 pandemic). The forward-looking statements in this Presentation are not guarantees or predictions of future performance and may involve significant elements of subjective judgment, assumptions as to future events that may not be correct, known and unknown risks, uncertainties and other factors, many of which are outside the control of Botanix.

Except as required by law or regulation, Botanix undertakes no obligation to finalize, check, supplement, revise or update forward-looking statements or to publish prospective financial information in the future, regardless of whether new information, future events or results or other factors affect the information contained in this Presentation.

6. No liability

The information contained in this document has been prepared in good faith by Botanix. Neither Botanix, nor any of its advisers or any of their respective affiliates, related bodies corporate, directors, officers, partners, advisers, employees and agents have authorised, permitted or caused the issue, lodgment, submission, dispatch or provision of this Presentation in a final form and none of them makes or purports to make any binding statement in this Presentation and there is no statement in this Presentation which is based on any statement by them.

To the maximum extent permitted by law, Botanix and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents:

expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any estimates or projections and any other financial information derived therefrom, whether by way of negligence or otherwise; and

expressly exclude and disclaim all liabilities in respect of, make no representations regarding, any part of this Presentation and make no representation or warranty as to the currency, accuracy, adequacy, reliability or completeness or fairness of any statements, estimates, options, conclusions or other information contained in this Presentation.

Botanix – Accelerating towards commercialization of SOFDRA™

DERMATOLOGY FOCUS

New treatments for underserved common skin diseases, with a first focus on excessive sweating (“primary axillary hyperhidrosis”)

TOPICALLY DRIVEN

Targeting key indications with topical (gel) treatments that are safe, well tolerated and validated with clinical efficacy

WORLD CLASS TEAM

US-based team that have been responsible for successful development and commercial launches of more than 30 dermatology drugs

NEW PRODUCT “SOFDRA”

SOFDRA is the first and only new chemical entity for primary axillary hyperhidrosis (5% product already approved in Japan with solid sales)¹


TARGETING MID-24 FDA APPROVAL

Submission of final component required for approval (the ‘Instructions for Use’) on target for Q1 CY2024, targeting FDA approval in mid-CY2024

Hyperhidrosis

A medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature

- ❖ Hyperhidrosis affects ~16M people in the US¹
- ❖ Results from overstimulation of the nervous system (a physiological not psychological condition)¹
- ❖ 90% of axillary (underarm) patients also have it in a second region¹
- ❖ The most common age of onset for axillary hyperhidrosis patients is 12–17²
- ❖ Market for treatments is ~\$US1.6B per annum—projected to grow to \$US2.8B by 2030²



FREQUENTLY
CHANGE
CLOTHES



FRESHEN UP
BY WIPING OR
BATHING



PLACE NAPKINS OR
PADS UNDER THEIR
ARMS OR THEIR
POCKETS




HIDE UNDER
DARK-COLOURED,
BULKY CLOTHES


Sofdra™ mechanism of action

Blocks sweat gland receptors and rapidly degrades for excretion

UNTREATED SWEAT GLAND



TREATED SWEAT GLAND




M3 AC Receptors = Muscarinic Acetylcholine Receptors which regulate the function of sweat glands

SB Metabolite = Sofpironium Bromide is converted into a less active form to help minimize side effects

Both Phase 3 clinical study co-primary endpoints were highly statistically significant

POOLED DATA (CARDIGAN I AND II)

≥2-point improvement in HDSM-Ax-7 from baseline to end of treatment¹




SB = Sofpironium Bromide

HDSM-Ax-7 scale measures patient reported severity of axillary (underarm) hyperhidrosis

POOLED DATA (CARDIGAN I AND II)

GSP change from baseline to end of treatment¹




GSP (Gravimetric Sweat Production) is an objective measurement of underarm sweat production (mg/ 5 min)

FDA Communication

Efficacy, safety and manufacturing all acceptable, one issue to address - patient use instructions

- ❖ The only area identified by FDA was related to the patient *Instructions for Use*
- ❖ No efficacy, safety, or manufacturing issues were raised, and no additional clinical studies are required by FDA to support NDA approval
- ❖ No new review issues are anticipated as part of the resubmission review and the requested activities can be quickly addressed
- ❖ Botanix will meet with FDA in November/December to confirm resubmission guidance
- ❖ On track to resubmit the NDA by early Q1 CY2024, with a target approval of mid-CY2024
- ❖ Anticipated delay in launch from 1Q CY2024 of 3-6 months, with no change in large market opportunity

Instructions for Use revision – well advanced and on target



- ❖ Revised the Instructions For Use to further simplify the guidance for application ✓
- ❖ Updated bottle label and carton to prominently display “wash hands with soap and water immediately after use” ✓
- ❖ Conducted a *pilot* human factors study to demonstrate the revised Instructions For Use are reliably followed ✓
- ❖ Filed an end-of-review meeting request with FDA to be held end of November/start of December CY 2023 ✓
- ❖ Preparing to commence human factors *validation* study to confirm revised Instructions for Use are reliably followed underway
- ❖ Preparing resubmission to FDA once completed study results are available targeted for early Q1 CY2024 underway

ersonal use only

Commercial preparation for Sofdra™ launch

Sofdra™ launch strategy

Rapidly establish Sofdra as a safe and effective first-line topical treatment of primary axillary hyperhidrosis, in patients 9 years of age and older

- Drive dermatology adoption through comprehensive engagement around a compelling clinical story
- Engage and motivate patients to take control of their hyperhidrosis and visit a physician for appropriate diagnosis and prescription
- Ensure favorable coverage with payers
- Provide patient access and immediate fulfillment through telemedicine and a dedicated pharmacy network, to drive trial and usage
- Hire and train a highly effective sales force and target accordingly

Significant opportunity for a new topical agent with class leading efficacy and safety




Due to its significant psychological impact, 54% of respondents suffering from hyperhidrosis say that they would pay anything for a treatment to stop their excessive sweating¹

Engagement with dermatologists supported by nonpersonal tactics

CLINICAL RE-PRINT

Arm field force with data



Article reprint with branded cover to facilitate early interactions with dermatologists


WEBSITE

Support field force interactions through print/digital channels



Provide full information on including core data and other dermatology resources to increase brand awareness

JOURNAL AD



Print and digital journal advertisements create and reinforce awareness among dermatologists

BANNER ADS




Strategically placed banner ads, to drive physicians to branded website


Engage consumers where they are already active

Launch integrated DTC campaign to drive targeted awareness and motivate patients to take action; drive rapid uptake of prescriptions

DIGITAL



Branded banner ads and updated website
Customized branded banner ads that drive target to website and online self-test



Branded/unbranded social media
Connect with patients and create a community

TRADITIONAL



Branded campaign ads
Advertisements designed for direct response placed in strategically targeted print/digital publications

PR



Drive positive discussion and coverage in consumer media. Strengthen relationships with community influencers. Establish Botanix as a leader and partner to the HH community

Ensuring favorable Payer coverage leading up to and post launch

Maximize coverage through strategic contracting

Pre-Approval Period

Confirm anticipated Payer management

- ❖ Confirm current management approach for HH therapies
- ❖ Identify potential contracting opportunities
- ❖ Clinical presentations as requested

PDUFA–Launch Period

Execute contracts

- ❖ Pricing and Product Fact Sheet
- ❖ Formulary kit
- ❖ Sales force training materials (Implementation Guides)
- ❖ Execute contracts with prioritized Payer accounts


Post-Launch Period

Contract for Favorable Coverage and Support Pull-Through

- ❖ Capitalize on formulary “wins” with sales force
- ❖ Continue discussions and execute contracts with prioritized accounts

Digital strategy—expands the addressable patient population


Personal-use only



Potential to diagnose and treat from home with telemedicine

Patients already in dermatologist's office that can be reached with a targeted sales force


Telehealth experience significantly speeds time to therapy



MOVE FROM THE CURRENT STATE OF WEEKS / MONTHS TO HOURS FOR A PRESCRIPTION


Target most productive prescribers & expand reach via digital

- ❖ Rapid scale-up of a new 20 - 30 rep field force to reach 4,500 high prescribing dermatologists
- ❖ Top sales professionals identified
- ❖ Recruiting ongoing for post approval start



Focused pre-launch period ahead

- ❖ FDA submission on track for 1Q CY2024, with approval targeted for mid-CY2024
- ❖ Only remaining issue to be addressed for FDA approval relates to patient Instructions for Use – no efficacy, safety or manufacturing issues
- ❖ Commercial preparation accelerating, given de-risking of FDA approval
- ❖ Company is funded to approval and has multiple commercialization options



ersonal use only

